Related Experiment Videos
Discovery of a novel Raf kinase inhibitor
J F Lyons1, S Wilhelm, B Hibner
1Onyx Pharmaceuticals, 3031 Research Drive, Richmond, California 94806, USA. jlyons1@ireland.com
Abstract:
We discuss the biology of Ras signal transduction and the epidemiology of ras mutations in association with disease as a background for the development of a Raf kinase inhibitor, BAY 43-9006. Knowledge of Ras effector pathways has permitted genetic validation of numerous targets involved in the Ras signaling cascade. A key Ras effector pathway involves the kinase cascade RAF/MEK/ERK (MEK: MAP/ERK kinase; ERK: extracellular signal related kinase). Indeed, we present studies of cell lines stably expressing mutant MEK constructs, which point to Raf kinase as a target for therapeutics with selective anti-tumor activity. Finally, a small molecule drug discovery program based on inhibition of Raf kinase activity is outlined and the initial pre-clinical development process of the Raf kinase inhibitor BAY 43-9006 is discussed.
Insights
This study explores Ras signal transduction and mutations, identifying Raf kinase as a therapeutic target. The development of BAY 43-9006, a novel Raf kinase inhibitor, demonstrates potential for selective anti-tumor activity.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Ras signal transduction pathways are crucial in cellular processes.
- Ras mutations are linked to various diseases, highlighting their oncogenic potential.
- Understanding Ras effector pathways, like the RAF/MEK/ERK cascade, is key for targeted therapies.
Purpose of the Study:
- To provide background on Ras biology and mutation epidemiology.
- To validate Raf kinase as a therapeutic target.
- To outline the development of a novel Raf kinase inhibitor, BAY 43-9006.
Main Methods:
- Review of Ras signal transduction and mutation epidemiology.
- Genetic validation of targets within the Ras signaling cascade.
- Pre-clinical development of the Raf kinase inhibitor BAY 43-9006.
Main Results:
- Raf kinase identified as a viable therapeutic target based on studies of cell lines with mutant MEK.
- BAY 43-9006 demonstrates selective anti-tumor activity in pre-clinical development.
- The drug discovery program successfully targeted Raf kinase activity.
Conclusions:
- Targeting Raf kinase offers a promising strategy for cancer therapy.
- BAY 43-9006 represents a significant advancement in the development of Raf kinase inhibitors.
- Further pre-clinical development of BAY 43-9006 is warranted.